Keros Therapeutics, Inc. (KROS)
10.78
-0.25
(-2.27%)
USD |
NASDAQ |
Aug 24, 16:00
10.79
+0.01
(+0.09%)
After-Hours: 20:00
Keros Therapeutics Debt to Equity Ratio : 0.0599 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0599 |
| March 31, 2026 | 0.0571 |
| December 31, 2025 | 0.0557 |
| September 30, 2025 | 0.0248 |
| June 30, 2025 | 0.0254 |
| March 31, 2025 | 0.0253 |
| December 31, 2024 | 0.033 |
| September 30, 2024 | 0.0362 |
| June 30, 2024 | 0.0332 |
| March 31, 2024 | 0.0313 |
| December 31, 2023 | 0.0435 |
| September 30, 2023 | 0.0484 |
| June 30, 2023 | 0.0428 |
| March 31, 2023 | 0.0394 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.0478 |
| September 30, 2022 | 0.0019 |
| June 30, 2022 | 0.0032 |
| March 31, 2022 | 0.004 |
| December 31, 2021 | 0.0045 |
| September 30, 2021 | 0.0059 |
| June 30, 2021 | 0.0029 |
| March 31, 2021 | 0.0032 |
| December 31, 2020 | 0.0034 |
| September 30, 2020 | 0.0076 |
| June 30, 2020 | 0.0077 |
| March 31, 2020 | -3.093 |
| December 31, 2019 | -1.346 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Incyte Corp. | 0.006 |
| Nurix Therapeutics, Inc. | 0.1444 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 287.60M |
| Total Liabilities (Quarterly) | 25.28M |
| Shareholders Equity (Quarterly) | 262.32M |
| Current Ratio | 21.96 |
| Net Debt Paydown Yield | 0.25% |